College of American Pathologists

2010—May Case of the Month

Posted October 07, 2010


CAP Foundation May 2010 Online Case of the Month

View case with:
PC users: ImageScope
First-time use of ImageScope?
* Download (required)

Why use ImageScope?

ImageScope offers many additional features including:

• Ability to view multiple slides
  concurrently; synchronize

• Facility to author annotations.

• Capability to run analysis
  algorithms, and display results.

• Modify image brightness,
  contrast, color balance,

• Generally faster and more

MAC/PC Users: WebViewer

After reading the summary, try answering the three related multiple-choice questions below.

A 42-year-old man presented with progressive change in personality, confusion, and difficulty walking. MRI of the brain showed diffuse high T2 signal throughout the white matter bilaterally, with only focal enhancement. Following a brain biopsy, he received radiation therapy but declined neurologically and died 30 months after initial diagnosis. At autopsy, the deep cerebral white matter was expanded bilaterally and the gray-white junction was indistinct.

Archive Case and Diagnosis: This case first appeared as Performance Improvement Program in Surgical Pathology (PIP) 2007, Case 8 and is a gliomatosis cerebri.

Criteria for Diagnosis and Comments: The diagnosis in this case is gliomatosis cerebri (GC). GC is a diffusely infiltrating glial tumor which involves more than two lobes, is frequently bilateral, and often extends into infratentorial structures. As such, correlation with clinical and radiographic findings is necessary to make an antemortem diagnosis. MRI with T2-weighted or FLAIR images is the most sensitive modality for diagnosis, revealing diffuse hyperintensity in more than two lobes. Recent studies have also suggested that magnetic resonance spectroscopy may be of value in diagnosis. Clinically, patients present with the insidious onset of headaches, seizures, corticospinal tract deficits, altered mental status and/or dementia.

Pathologically, GC most often involves the cerebral hemispheres (76% of cases), with the centrum semiovale always involved and less frequent infiltration of the cortex (19%) and leptomeninges (17%). The mesencephalon and pons are involved in 52% of cases, thalamus in 43%, basal ganglia in 34%, cerebellum in 29%, medulla oblongata in 13% and the spinal cord in 9%. Grossly, there is diffuse expansion of the white matter with loss of gray-white matter demarcation and relative preservation of the underlying architecture. In the classical form, designated type I by WHO, no circumscribed tumor masses are present. A secondary circumscribed tumor mass, usually with malignant features, may develop in some cases, classified as Type II GC by the WHO. Histologically, GC is characterized by diffuse white matter infiltration by elongated glial cells, which often form parallel rows among nerve fibers in myelinated tracts. Myelin sheaths may be destroyed, but axons and neurons are preserved. When the cortex is involved, perineuronal satellitosis and subpial infiltration may be prominent. The neoplastic cells have ovoid, hyperchromatic nuclei with indistinct nucleoli and mitotic activity is variable. In some cases, gemistocytic tumor cells may be present. In most cases, the neoplastic cells appear to be astrocytic, although they may be GFAP-negative. A smaller percentage of cases (22% in men and 13% in women) exhibit an oligodendroglial morphology and/or genotype. Some cases may exhibit TP53 mutations or p53 nuclear protein accumulation, similar to diffuse astrocytomas, but other molecular genetic alterations are rare. Chromosomal analysis suggests a clonal origin, with the findings not being typical of astrocytoma. As such, GC is classified under “Glial tumors of uncertain origin” by the WHO. The prognosis in GC is poor and it has been classified as WHO grade III. In a recent study, median survival was 14.5 months, with longer survival (36 months) for the oligodendroglial type. Infratentorial involvement and higher Ki-67 labelling index are associated with shorter survival. Some patients show a benefit from chemotherapy or whole brain radiotherapy.

In the current case, the neoplastic cells have an astrocytic appearance, with elongate, hyperchromatic nuclei in a fibrillary background. As such, the diagnosis of oligodendroglioma, which has uniform, round nuclei, is excluded. Although nuclear pleomorphism is present, this neoplasm lacks the mitotic activity seen in anaplastic astrocytoma and the vascular proliferation and necrosis seen in glioblastoma. Further, the radiologic and autopsy findings, with diffuse, bilateral white matter involvement, support the diagnosis of GC rather than diffuse astrocytoma. Late-delayed radiation necrosis, which usually develops 6 months to 2 years after completion of therapy, is characterized by white matter necrosis, fibrinoid angionecrosis, glomeruloid vascular proliferation, thickening and fibrosis of vascular walls, and reactive gliosis. Although this lesion may extensively involve white matter, it is usually contrast enhancing. Further, the current case lacks the necrosis and vascular changes seen with radiation necrosis.

Supplementary Questions For each of the following, select the most likely diagnosis from the diagnostic set (an answer may be used once, more than once, or not at all).

Question Diagnostic Set
1. Which of the following is NOT characteristic of gliomatosis cerebri? A. Diffuse white matter infiltration
B. Hyperintensity on T2-weighted MRI
C. Involvement of 2 or more lobes
D. Poor prognosis
E. Vascular proliferation and necrosis
2. Gliomatosis cerebri most often involves which of the following? A. Centrum semiovale
B. Mesencephalon
C. Pons
D. Spinal cord
E. Thalamus
3. Which of the following is NOT characteristic of late-delayed radiation necrosis? A. Angiofibrosis
B. Cerebral cortical neuronal degeneration
C. Fibrinoid angionecrosis
D. Reactive gliosis
E. White matter necrosis


  1. Herrlinger U, FelsbergJ, Kuker W, et al. Gliomatosis cerebri: Molecular pathology and clinical course. Ann Neurol. 2002;52:390-399.
  2. Kim DG, Yang HJ, Park IA, et al. Gliomatosis cerebri: Clinical features, treatment, and prognosis. Acta Neurochir (Wien). 1998;140:755-762.
  3. Lantos PL, Bruner JM. Gliomatosis Cerebri. In: Kleihues P, Cavenee WK, eds. World Health Organization Classification of Tumours. Pathology and Genetics: Tumours of the Nervous System. Lyon, France: IARC Press; 2000:92-93.
  4. Mawrin Cc, Kirches E, Schneider-Stock R, et al. Analysis of TP53 and PTEN in gliomatosis cerebri. Acta Neuropathol (Berl). 2003;105:529-536.
  5. Sanson M, Cartalat-Carel S, Taillibert S, et al. Initial chemotherapy in gliomatosiscerebri. Neurology. 2004;63:270-275.
  6. Taillibert S, Chodkiewicz C, Laigle-Donadey F, et al. Gliomatosis cerebri: A review of 296 cases from the ANOCEF database and the literature. J Neurooncol. 2006;76:201-205.

Gary S. Pearl, M.D., Ph.D.
Surgical Pathology Committee
Orlando Regional Healthcare
Orlando, FL